FIELD: medicine.
SUBSTANCE: presented group of inventions refers to medicine. There are presented agents for inhibiting the alveolar airspace gain and an agent for inhibiting the alveolar wall destruction, containing adiponectin.
EFFECT: presented group of inventions provides the new therapeutic agent for treating the lung diseases accompanied by an irreversible lung function deterioration.
4 cl, 2 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE WITH BIOLOGICAL ACTIVITY OF INHIBITOR OF COLLAGEN-INDUCED ADHESION OF PLATELETS, ITS PREPARING AND USING | 2000 |
|
RU2292351C2 |
| ANTI-PSGL-1-ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2650817C2 |
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| NOVEL MUTANT OF RECOMBINANT IMMUNOMODULATORY PROTEIN GANODERMA LUCIDUM AND USE THEREOF | 2022 |
|
RU2841540C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| αvβ3 INTEGRIN SELECTIVE POLYPEPTIDES CONJUGATED WITH VARIANT OF HUMAN SERUM ALBUMIN (HSA), AND THEIR PHARMACEUTICAL APPLICATIONS | 2010 |
|
RU2547592C2 |
| IMMUNITY-INDUCING AGENT | 2012 |
|
RU2634862C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
